Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)

Assesses adults diagnosed with rheumatoid arthritis (RA) who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD).

Why It Matters

RA is a chronic inflammatory disease in which the immune system attacks healthy joints.1 It causes inflammation and destruction of joints and can also damage organs.2 RA is progressive, but early intervention with DMARDs can help preserve function and prevent further damage to joints.2

Results

DMARD TREATMENT RATE
Commercial Medicaid Medicare
Year HMO PPO HMO HMO PPO
2017 88.8 87.9 73.9 77.5 78.5
2016 87.8 87.1 73.1 76.8 77.8
2015 88.3 87.8 71.7 77.1 78.8
2014 88.1 87.3 69.5 76.7 80.5
2013 88.1 87.2 70.6 76.2 80.2
2012 87.9 87.2 69.9 75.5 78.8
2011 87.6 86.7 68.9 72.7 77.2
2010 87.7 87.0 70.1 72.8 77.8
2009 86.4 86.6 70.5 72.3 76.4
2008 85.7 81.5 69.4 70.4 75.1
2007 85.3 78.9 68.1 68.7 73.5
2006 84.8 82.3 67.6 68.2 69.7

References

  1. Centers for Disease Control and Prevention. 2012. “Rheumatoid Arthritis.” http://www.cdc.gov/arthritis/basics/rheumatoid.htm
  2. American College of Rheumatology. 2012. “Rheumatoid Arthritis.” http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp

  • Save

    Save your favorite pages and receive notifications whenever they’re updated.

    You will be prompted to log in to your NCQA account.

  • Email

    Share this page with a friend or colleague by Email.

    We do not share your information with third parties.

  • Print

    Print this page.